
    
      In this study with 450 patients with primary or secondary immunosuppressive disorders
      (patients with primary immunodeficiency, HIV infected patients, patients with allogenic stem
      cell transplantation/CAR T cell treated, solid organ transplanted, and patients with chronic
      lymphatic leukemia) from Karolinska University Hospital, and healthy controls of 90
      individuals for comparison, we will investigate the safety and the immune responses after
      mRNA vaccination with Comirnaty after two doses, under 6 months of time for each participant.
      The study is In collaboration with research groups at Karolinska Institutet and SciLifeLab,
      with planned in-depth detailed analyses of antibody responses as well as cellular responses.
      The study has obtained permission from Swedish Medical Agency and Swedish Ethical Review
      Authority.
    
  